ASCO insights on T-DXd plus pertuzumab in HER2-positive breast cancer: deep, durable responses and practical ILD/radiation safety considerations.
Ami Shah, MD
Advertisement
Articles by Ami Shah, MD
New phase III data reshapes HER2+ breast cancer care, spotlighting T-DXd from neoadjuvant to first-line metastatic, plus CNS and toxicity insights.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Afami-cel in Metastatic Synovial Sarcoma
2
The Moonlight Shift: Dr Joshua Richter on Myeloma, Myths, and the C-Word
3
Binimetinib Tablets Receive Tentative FDA Approval in Melanoma/NSCLC
4
How Are Key Lymphoma Data From ASCO and EHA 2026 Shaping Treatment?
5